Evidence map›Paper›PMID 39762638›Full record

ArticleLung2025

Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.

Chiara Lanfranchi, Gianfranco Alicandro, Lisa Cariani, Beatrice Silvia Orena, Andrea Gramegna, Carmela Rizza, Francesco Blasi, Valeria Daccò

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiara LanfranchiMother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Gianfranco AlicandroMother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Lisa CarianiMicrobiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Beatrice Silvia OrenaMicrobiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Andrea GramegnaDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Carmela RizzaMother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Francesco BlasiDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Valeria DaccòMother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. valeria.dacco@policlinico.mi.it.

Funding

The Italian Ministry of Education and Research 'Dipartimenti di Eccellenza' Programme 2023-27 - Dept. of Pathophysiology and Transplantation, Università degli Studi di Milano
6 · The paper itself

Abstract

purposeThe study evaluated the effects of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in people with cystic fibrosis (pwCF) and a clinical history of Aspergillus fumigatus (AF) infection.

methodsThis prospective cohort study included pwCF who initiated ETI therapy and had received antifungal treatment in the preceding five years due to allergic bronchopulmonary aspergillosis (ABPA group) or other AF-related clinical manifestations (AF group). A control group of pwCF with no prior respiratory cultures positive for AF was also included. Changes from baseline to 12 months in spirometry measures and lung clearance index (LCI

resultsThe study included 16 patients in the ABPA group, 47 in the AF group, and 45 controls. Spirometry and LCI

conclusionDuring ETI therapy, pulmonary outcomes improved, AF colonization and sensitization decreased, and no episodes of ABPA were observed in pwCF with a clinical history of AF infection.

Indexed as

AminophenolsAntifungal AgentsAspergillosis, Allergic BronchopulmonaryAspergillus fumigatusBenzodioxolesCystic FibrosisDrug CombinationsIndolesQuinolonesAdolescentAdultAntibodies, FungalChlorobenzenesFemaleForced Expiratory VolumeHumansAminophenolsAntibodies, FungalAntifungal AgentsBenzodioxolesChlorobenzenesDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationImmunoglobulin EImmunoglobulin GIndolesPyrazolesPyridinesPyrrolidinesQuinolinesQuinolonesABPAAspergillosisAspergillusCFTR modulatorsCystic fibrosisElexacaftorIvacaftorSensitizationSerologyTezacaftor

Identifiers

PMID39762638

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.